Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy

BACKGROUND: Targeted disease-modifying antirheumatic drug (DMARD) options for rheumatoid arthritis (RA) include tumor necrosis factor (TNF) inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab) or alternative mechanisms of action (MOAs), such as a T-cell co-stimulation modulator (...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Am Health Drug Benefits
Hoofdauteurs: Bonafede, Machaon M. K., McMorrow, Donna, Proudfoot, Clare, Shinde, Shraddha, Kuznik, Andreas, Chen, Chieh-I
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Engage Healthcare Communications, LLC 2018
Onderwerpen:
Business
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6207310/
https://ncbi.nlm.nih.gov/pubmed/30464787
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items